A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer
Tim Meyer(The Royal Free Hospital), Hiroki Kato(Zeria Pharmaceutical (Japan)), Justin S. Waters(Maidstone Hospital), Marc Peeters(University of Antwerp), Daniel H. Palmer(University of Liverpool), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), Erika Nagano, Juan W. Valle(Cancer Research UK Manchester Institute), Michael Larvin(University of Nottingham), Martyn Caplin(The Royal Free Hospital), Ivan Borbath
Cited by 39
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k